Table 4.

The association between potential mediators and hip fracture adjusted for the base analysis^† and number of high^¶ inflammatory markers

	Risk Ratios	95% CIs
Frailty (N pairs=358)	1.36	0.86–2.16
RAND 36 Physical Functioning >90 (N pairs = 344)	0.65	0.43–1.01
Total number of falls at follow-up (N pairs = 333)	0.97	0.92–1.02
Bioavailable estradiol, pg/ml (N pairs=348)	0.96	0.92–1.00
Bioavailable testosterone, pg/ml (N pairs=355)	0.97	0.94–0.99
SHBG, μg/dl (N pairs=356)	1.41	1.13–1.75
Cystatin-C, ng/ml (N pairs=353)	1.49	0.63–3.54
PINP, ng/ml (N pairs=345)	1.00	0.99–1.01
CTx, ng/ml (N pairs=348)	1.48	0.63–3.50
25(OH)D, ng/ml (N pairs=357)	0.97	0.95–1.00

N indicates number of case-control pairs included in the analysis.

^†Base analysis was matched on age, ethnicity, blood draw date, controlled for BMI, self-reported health, physical activity, parental history of hip fracture, history of fracture, smoking, alcohol use, NSAID use, treated diabetes, RA, corticosteroid use, and total calcium and vitamin D intake.

^¶Number of inflammatory markers in the top quartile according to the distribution of cytokine soluble receptor concentrations among the controls.